Investors building exposure to the healthcare sector often face a familiar dilemma: cast a wide net for diversification or zero in on high-growth niches. Four popular ETFs — the iShares Global Healthcare ETF (IXJ), the Invesco Nasdaq Biotechnology ETF (IBBQ), the Invesco Pharmaceuticals ETF (PJP) and the Vanguard Health Care ETF (VHT) — each embody a distinct path. Below is a detailed comparison across fees, returns, risk and portfolio construction.
VHT stands out as the most affordable option, charging just 0.09% annually. IBBQ follows at 0.19%, undercutting IXJ’s 0.40% fee. The most expensive of the group is PJP, with an expense ratio of 0.57%. For income-seeking investors, the picture reverses: VHT delivers the highest trailing 12-month dividend yield at 1.60%, closely trailed by IXJ at 1.50%. PJP offers 0.90%, while IBBQ yields the least at 0.80%. In terms of scale, VHT is the giant, commanding $20.4 billion in assets, compared with $4.0 billion for IXJ, $435.5 million for PJP and just $75.4 million for IBBQ.
The return gap has been stark over the past year. As of July 20, 2026, IBBQ posted a one-year total return of 47.50%, and PJP was right behind at 45.10% — both well ahead of VHT’s 25.20% and IXJ’s 18.30%.
Looking across multiple timeframes, the momentum persists. Year-to-date, IBBQ had risen 15.3%, while IXJ managed only 2.0%. Over three years, IBBQ delivered an 18% cumulative return versus 6.6% for IXJ; on the pharmaceutical side, PJP gained 17.3% compared with VHT’s 8.6%. Annualized over five years, PJP led the pack at 9.1%, followed by IBBQ at 5.7%, VHT at 5.4% and IXJ at 4.9%. Over a full decade, PJP’s annualized return reached 7.5%.
A $1,000 investment five years ago would have grown to $1,540 in PJP, $1,295 in IBBQ, $1,281 in VHT and $1,243 in IXJ.
High returns come with a warning label. IBBQ recorded a maximum drawdown of 38% over the past five years, more than double the losses suffered by the other three. IXJ, VHT and PJP all endured drawdowns within a narrow band — 18.10%, 17.70% and 17.50%, respectively — reflecting stronger downside resilience. Beta readings relative to the S&P 500 tell a similar story: PJP registered the lowest beta at 0.45, meaning it was the least sensitive to broad market swings. IXJ came next at 0.56, while both IBBQ and VHT carried a beta of 0.60.
The four funds differ radically in breadth and size tilt. IXJ holds 110 stocks spanning pharmaceuticals, biotechnology and medical devices; roughly three-quarters of assets are in U.S. equities, with the rest in developed markets and just 1% in emerging markets. Small caps make up a negligible 1% of the portfolio, and mid caps account for 16%.
IBBQ, tracking the Nasdaq Biotechnology Index, owns 251 names and is nearly all U.S.-listed. It leans heavily toward smaller innovative companies: 38% of assets sit in small caps and another 36% in mid caps.
VHT casts the widest net with 411 holdings, nearly all in healthcare. Large-cap value stocks dominate at 67% of assets, while small caps represent just 12%.
PJP takes the opposite approach, concentrating on just 29 pharmaceutical stocks. Despite the narrow focus, 43% of the portfolio is in small caps, matching its 43% large-cap exposure — a structure that has allowed it to capture sharp upside without extreme beta.
All four count Eli Lilly, Johnson & Johnson and AbbVie among their top holdings, but weightings differ sharply. VHT allocates 14.2% to Eli Lilly alone, creating meaningful single-stock concentration. PJP, by contrast, caps each position at no more than 5.6%, keeping the top-heavy risk in check.
IBBQ and PJP have delivered standout total returns over the past one, three and five years, making them compelling for investors willing to stomach volatility for higher growth potential. PJP is particularly notable for pairing market-beating returns with the lowest beta in the group. However, IBBQ’s 38% drawdown is a reminder that biotech-heavy portfolios can experience severe swings.
For those who prioritize stability, steady income and rock-bottom costs, VHT and IXJ remain strong choices. VHT offers the lowest expense ratio, the highest dividend yield and massive scale, while IXJ adds a layer of global diversification with mild drawdowns and a healthy 1.50% yield. The decision ultimately rests on whether one leans toward the higher-octane growth of IBBQ and PJP, or the steadier compounding of VHT and IXJ.
